# Study of Dupilumab Auto-injector Device When Used by Patients With Atopic Dermatitis

> **NCT03050151** · PHASE1 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 176 (actual)

## Conditions studied

- Atopic Disorders
- Eczema, Atopic

## Interventions

- **DRUG:** Dupilumab
- **DEVICE:** Auto-injector Device
- **DEVICE:** Prefilled syringe

## Key facts

- **NCT ID:** NCT03050151
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-28
- **Primary completion:** 2017-11-14
- **Final completion:** 2018-02-12
- **Target enrollment:** 176 (ACTUAL)
- **Last updated:** 2018-08-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03050151

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03050151, "Study of Dupilumab Auto-injector Device When Used by Patients With Atopic Dermatitis". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03050151. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*